Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program

Oncology

Volumn 78, Issue 5-6, 2010, Pages 340-347

  Bukowski, Ronald M ^a   Stadler, Walter M ^c   McDermott, David F ^d   Dutcher, Janice P ^e   Knox, Jennifer J ^q   Miller Jr , Wilson H ^r   Hainsworth, John D ^f   Henderson, Charles A ^g   Hajdenberg, Julio ^h   Kindwall Keller, Tamila L ^b   Ernstoff, Marc S ⁱ   Drabkin, Harry A ^j   Curti, Brendan D ^k   Chu, Luis ^m   Ryan, Christopher W ^l   Hotte, Sebastien J ^s   Xia, Chenghua ⁿ   Cupit, Lisa ^o   Figlin, Robert A ^p  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g Peachtree Hematology Oncology Consultants   (United States)

^h M D ANDERSON CANCER CENTER ORLANDO   (United States)

ⁱ DARTMOUTH MEDICAL SCHOOL   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k EARLE A CHILES RESEARCH INSTITUTE   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m Florida Cancer Specialists   (United States)

ⁿ Bayer HealthCare Pharmaceuticals Inc   (United States)

^o Bayer Pharmaceuticals Corporation   (United States)

^p CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^q UNIVERSITY OF TORONTO   (Canada)

^r MCGILL UNIVERSITY   (Canada)

^s MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Elderly; Metastasis; Protein kinase inhibitor; Renal cell carcinoma; Sorafenib

Indexed keywords

BEVACIZUMAB; INTERFERON; INTERLEUKIN 2; SORAFENIB; SUNITINIB; THALIDOMIDE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DESQUAMATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEALTH PROGRAM; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, RENAL CELL; ETHNIC GROUP; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SAFETY; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; ETHNIC GROUPS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS; KAPLAN-MEIER ESTIMATE; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77956084780     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320223     Document Type: Article

References (22)

1. Cancer facts and figures 2009. Atlanta, American Cancer Society, 2009. http://www. cancer.org/downloads/STT/500809web.pdf (accessed August 3, 2009).
2. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1:CD001425.
3. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2009. http://www. nccn.org/professionals/physician- gls/f- guidelines.asp (accessed November 12, 2009).
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negriér S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Négrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
6. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Négrier S, Huang X, Kim ST, Chen I, Motzer RJ: Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) (abstract 5024). J Clin Oncol 2008; 26(May suppl):abstract 5024.
7. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon 2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
8. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
10. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
11. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M: Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 1855-1861.
12. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472-5480.
13. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688-1694.
14. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
15. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sora fenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
16. Bukowski R, Cella D, Gondek K, Escudier B: Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007; 30: 220-227.
17. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-1280.
18. Lynch CF, West MM, Davila JA, Platz CE: Cancers of the kidney and renal pelvis; in Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner M-J (eds): SEER Survival Monograph. Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, National Cancer Institute Seers Program, 2007, chapt 24, pp 193-202.
19. Nese N, Paner GP, Mallin K, Ritchey J, Stewart A, Amin MB: Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. Ann Diagn Pathol 2009; 13: 1-8.
20. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B: Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008; 100: 1454-1463.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
22. Townsley CA, Pond GR, Oza AM, Hirte HW, Winquist E, Goss G, Degendorfer P, Moore MJ, Siu LL: Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res 2006; 12: 2141-2149.